Bio-Rad Laboratories, Inc.Class A BIO
Analyst Ratings
- Consensus
- Hold — 1 Buy · 2 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $350.00 (-8.5% downside)
Key Stats
- Today's Range
- $377.69 – $385.71
- 50-Day Range
- $284.23 – $396.23
- 52-Week Range
- $236.73 – $396.23
- Volume
- 205K shs
- Average Volume
- 256K shs
- Market Cap
- $10.13 billion
- P/E Ratio
- 46.58
- Dividend Yield
- —
Valuation
- P/E Ratio
- 46.58
- Price / Book
- 1.41
- Price / Sales
- 3.91
Short Interest
- Short Interest
- 2.44%
- Days to Cover
- 2.54
Financials (TTM)
- Revenue
- $2.59 billion
- Net Income
- $222.40 million
- Net Margin
- 8.59%
- Return on Equity
- 3.10%
- Debt-to-Equity
- 0.17
About Bio-Rad Laboratories, Inc.Class A
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Related Stocks
Compare head-to-head: BIO vs WAT·BIO vs TXG·BIO vs BRKR·BIO vs CTKB
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.